Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast
Genocea Biosciences (NASDAQ: GNCA) will host a conference call on July 23, 2020, at 8:30 a.m. EDT to discuss its Q2 2020 financial results and corporate updates. Interested participants can join by calling (844) 826-0619 (domestic) or (315) 625-6883 (international) with conference ID 8894505, or through a live audio webcast available on their website. Genocea focuses on developing neoantigen immunotherapies for cancer, with its ATLAS platform enhancing the targeting of tumor antigens. The company is advancing two clinical programs, GEN-009 and GEN-011, with preliminary results expected in Q3 2020 and mid-2021, respectively.
- None.
- None.
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, July 23rd at 8:30 a.m. EDT.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8894505. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and expect preliminary clinical results in the third quarter of 2020, and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood and expect preliminary clinical results in mid-2021. To learn more, please visit www.genocea.com.
Forward-Looking Statements
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com
FAQ
When is Genocea Biosciences' Q2 2020 conference call?
How can I access the Genocea conference call?
What is the focus of Genocea's ATLAS platform?
What clinical programs is Genocea advancing?
Where can I find more information about Genocea?
